Children and teens with abnormal heart rhythms are more likely to have depression, anxiety and attention deficit hyperactivity disorder, known as ADHD, according to a new study. The preliminary findings follow previous research suggesting the same higher rates for those conditions in young adults born with structural heart defects...The research is being presented Monday at the American Heart Association's Scientific Sessions conference in Philadelphia.

There appears to be no increased risk for serious cardiovascular events associated with stimulant medication use by children and adolescents with autism spectrum disorder (ASD), according to new research. In an analysis of more than 300,000 ASD patients, the incidence rate of serious cardiac events was approximately 0.01%, a rate that was statistically comparable for ASD patients who were taking stimulant medications and their counterparts who were not taking such medications.

Researchers in Singapore have recently created a system that combines neuromonitoring with video games to improve symptoms among patients with attention deficit hyperactivity disorder (ADHD). This team consisted of scientists from the country’s Institute of Mental Health (IMH), Duke-NUS (National University of Singapore) Medical School, and A*STAR (Agency for Science, Technology, and Research). Neeuro Pte Ltd. is a Singapore-based company that is commercializing this technology, which was summarized in a research article published in the journal PLOS One.

The update to the clinical practice guidelines is the first since 2011, and changes focus on the evaluation, diagnosis, and treatment of ADHD in children aged 4 to 18 years. Although there are no major changes to how ADHD is managed, the guidelines highlight the need to address issues that the child may be experiencing outside of ADHD, such as learning and language disorders, anxiety, depression, and autism.

The findings are “extremely important for us, and helps us understand very well the pattern of how this drug behaves in these different populations, according to age and weight and so forth,” Supernus President and CEO Jack Khattar said in March. An FDA approval to commercialize the treatment — whose active ingredient, viloxazine hydrochloride, was marketed for years in Europe as an antidepressant — could make it “the first novel treatment to be introduced in the ADHD market in more than a decade,” Khattar said in a statement Monday.

Your brain has 1,000 tabs open at once, and you’re not sure which one to click on — work? love? cute animal videos? But is this overload just life, or is it something else? If your lack of concentration is constant and overwhelming, and you think you might be causing stress to those around you, then it’s time to get checked out for hyperactivity.

Years after Texas Education officials pledged to undo a decade worth of damage caused by a cap on special education services, the state remains in violation of federal disability laws. School district administrators are still clamoring for guidance and funding. And parents are still complaining that they’ve had to beg or threaten to sue in order to get their children evaluated for extra help in the classroom.